Major review finds little benefit of remdesivir in people hospitalised with COVID-19

Simon Collins, HIV i-Base

A final update to this ongoing review of randomised controlled trials using remdesivir concludes that In hospitalised adults with COVID-19, remdesivir probably results in little to no difference in mortality.

Although remdesivir may reduce time to clinical improvement and may lead to small reductions in serious adverse events it may also results in a small increase in any adverse event.

Reference

Kaka AS et al. Major update 2: remdesivir for adults with COVID-19: A living systematic review and meta-analysis for the American College of Physicians. Ann Intern Med. [Epub ahead of print 1 March 2022]. doi:10.7326/M21-4784.
https://www.acpjournals.org/doi/10.7326/M21-4784